Brief: Captor Therapeutics Informs NCBiR Of Potential Irregularities In EU Project Costs

Captor Therapeutics SA

27/01/2022 07:44

Jan 27 (Reuters) - Captor Therapeutics SA  CTXP.WA :
    * SAID ON WEDNESDAY IT HAS INFORMED POLAND'S NATIONAL CENTRE
FOR
RESEARCH AND DEVELOPMENT (NCBIR) OF RISK OF POTENTIAL
IRREGULARITIES TO SETTLING ELIGIBLE COSTS WITH NCBIR REGARDING
EU PROJECTS (PROJECTS)
    * SAID POTENTIAL IRREGULARITIES REGARD COMPANY'S HISTORICAL
ACTIVITIES AND DO NOT IMPACT RESULTS OF R&D CONDUCTED BY COMPANY
    * COMPANY HAS COMMISSIONED AN AUDIT TO THE ABOVE AND WILL
CONSIDER
APPLYING FOR STATUS OF WRONGED PARTY AND IF AUDIT CONFIRMS
IRREGULARITIES ALSO LEGAL PROTECTION OF ITS RIGHTS
    * SCOPE OF POTENTIAL IRREGULARITIES HAS NOT YET BEEN DEFINED
    * ACCORDING TO MANAGEMENT, IF AUDIT CONFIRM IRREGULARITIES,
COORDINATION WITH NCBIR SHOULD ENABLE CONTINUATION OF PROJECTS
AND MITIGATE FURTHEST EXTENT OF RISK OF RETURNING PART OF
SUBSIDIES
    * POTENTIAL IRREGULARITIES ARE NOT LINKED TO SUBSTANTIVE OR
QUALITATIVE SCOPE OF PROJECTS

    
    
 Source text for Eikon:  urn:newsml:reuters.com:*:nEM27d243a
 Further company coverage:  CTXP.WA  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))